HIGH-DOSE RADIOIMMUNOTHERAPY OF RELAPSED B-CELL LYMPHOMAS

被引：0
|
作者：
PRESS, OW
机构：
[1] UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195
[2] FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 1995年 / 210卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：11 / NUCL
相关论文
共 50 条
  • [31] RADIOIMMUNOTHERAPY OF B-CELL LYMPHOMA
    EARY, JF
    ANNALS OF ONCOLOGY, 1991, 2 : 187 - 190
  • [32] Another disappointment in treating relapsed, refractory high-risk aggressive B-cell lymphomas
    Eyre, Toby A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (02) : 202 - 204
  • [33] Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
    Morin, Ryan D.
    Assouline, Sarit
    Alcaide, Miguel
    Mohajeri, Arezoo
    Johnston, Rebecca L.
    Chong, Lauren
    Grewal, Jasleen
    Yu, Stephen
    Fornika, Daniel
    Bushell, Kevin
    Nielsen, Torsten Holm
    Petrogiannis-Haliotis, Tina
    Crump, Michael
    Tosikyan, Axel
    Grande, Bruno M.
    MacDonald, David
    Rousseau, Caroline
    Bayat, Maryam
    Sesques, Pierre
    Froment, Remi
    Albuquerque, Marco
    Monczak, Yury
    Oros, Kathleen Klein
    Greenwood, Celia
    Riazalhosseini, Yasser
    Arseneault, Madeleine
    Camlioglu, Errol
    Constantin, Andre
    Pan-Hammarstrom, Qiang
    Peng, Roujun
    Mann, Koren K.
    Johnson, Nathalie A.
    CLINICAL CANCER RESEARCH, 2016, 22 (09) : 2290 - 2300
  • [34] HIGH-DOSE RITUXIMAB IN THE CONDITIONING REGIMEN BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED B-CELL LYMPHOMAS IS ASSOCIATED WITH REDUCED GVHD-RELATED DEATHS, BUT DID NOT IMPROVE DISEASE CONTROL
    Dodero, A.
    Spina, F.
    Sarina, B.
    Carniti, C.
    Patriarca, F.
    Carella, A. M.
    Levis, A.
    Bosi, A.
    Falda, M.
    Di Raimondo, F.
    Di Bartolomeo, P.
    Dalto, S.
    Bacigalupo, A.
    Rambaldi, A.
    Corradini, P.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S288 - S288
  • [35] Mabtera (rituximab) treatment of patients with refractory B-cell lymphomas on high-dose chemotherapy with autologous transplantation of hemopoiesis precursor cells
    Ptushkin, VV
    Chimishkyan, KL
    Zhukov, NV
    Osmanov, DS
    Andreeva, LY
    Tupitsyn, NN
    Larionova, VB
    Mkheidze, DM
    Poddubnaya, IV
    TERAPEVTICHESKII ARKHIV, 2003, 75 (01) : 65 - 68
  • [36] A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results
    Srour, Samer A.
    Li, Shaoying
    Popat, Uday R.
    Qazilbash, Muzaffar H.
    Lozano-Cerrada, Sara
    Maadani, Farzeneh
    Alousi, Amin
    Kebriaei, Partow
    Anderlini, Paolo
    Nieto, Yago
    Jones, Roy
    Shpall, Elizabeth
    Champlin, Richard E.
    Hosing, Chitra
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (04) : 561 - 570
  • [37] High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis
    Gopal, AK
    Gooley, TA
    Maloney, DG
    Petersdorf, SH
    Eary, JF
    Rajendran, JG
    Bush, SA
    Durack, LD
    Golden, J
    Martin, PJ
    Matthews, DC
    Appelbaum, FR
    Bernstein, ID
    Press, OW
    BLOOD, 2003, 102 (07) : 2351 - 2357
  • [38] Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
    El Gnaoui, T.
    Dupuis, J.
    Belhadj, K.
    Jais, J.-P.
    Rahmouni, A.
    Copie-Bergman, C.
    Gaillard, I.
    Divine, M.
    Tabah-Fisch, I.
    Reyes, F.
    Haioun, C.
    ANNALS OF ONCOLOGY, 2007, 18 (08) : 1363 - 1368
  • [39] Radioimmunotherapy with 131-I tositumomab enhanced survival in good prognosis relapsed and high-risk diffuse large B-cell lymphoma (DLBCL) patients receiving high-dose chemotherapy and autologous stem cell transplantation
    Vose, J.
    Bierman, P.
    Bociek, G.
    Loberiza, F.
    Enke, C.
    Hankins, J.
    Armitage, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Myeloablative Anti-CD20 Radioimmunotherapy plus /- High-Dose Chemotherapy Followed by Autologous Stem Cell Support for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival
    Wagner, Julia Y.
    Schwarz, Kathleen
    Schreiber, Susanne
    Schmidt, Burkhard
    Wester, Hans-Juergen
    Schwaiger, Markus
    Peschel, Christian
    von Schilling, Christoph
    Scheidhauer, Klemens
    Keller, Ulrich
    ONCOTARGET, 2013, 4 (06) : 899 - 910
12345